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Triple negative breast cancer (TNBC) is a highly aggressive type of breast cancer with 
urgent clinical need for effective therapies. Resistance to standard clinical therapies with 
metastatic TNBC pushed the researchers to explore combinatorial therapy regime. A 
combination of STAT-3 specific inhibitor, reported to act synergistically with metformin in 
reducing cell growth and inducing apoptosis in TNBCs and agents targeting DNA repair, can 
produce a new approach to TNBC therapy. Towards this aim, we have generated a combinatorial 
drug formulation comprising DNA damage repair agents, along with inhibitors for STAT-3 for 
an optimized effect. The combinatorial formulation includes nifuroxazide, a known STAT-3 
inhibitor, and amonafide, an agent known to exert its effect through topoisomerase-II activation 
pathways. An additional incorporation of pentoxifylline, a methylxanthine derivative known for 
anti-metastatic effects in breast cancers, could further improve the efficiency. We used drug 
combination of nifuroxazide, amonafide and pentoxifylline in MDA-MB-231, HCC1806, 
HCC1143 and BT-549 TNBCs along with normal breast cells, MCF-7 and SkBr3, to find the 
combinatorial index of the drug cocktail. It was found that combination of pentoxifylline, 
nifuroxazide and amonafide resulted in a combinatorial index of 0.82 in HCC1806 cells. We also 
investigated the gene and protein expression effects exerted by combination of drugs responsible 
to induce synergistic effect and simultaneously suppressing drug resistance through distinct 
mechanisms of action.  
Next, we  demonstrate  that phenotypically  stratified carbon nanoparticle  is  highly  
effective  in  delivering  a  novel combinatorial  triple  drug  formulation  for  synergistic  
regression  of  TNBC in vitro and in vivo. The combinatorial formulation is comprised of 
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repurposed inhibitors of STAT3 (nifuroxazide), topoisomerase-II-activation-pathway 
(amonafide) and NFkb (pentoxifylline).  Synergistic effect of drug combination  was  established  
in  a  panel of TNBC-lines comprising mesenchymal-stem-like, mesenchymal and basal-like 
cells along with non-TNBC-cells. The delivery of combinatorial drug formulation was achieved 
using a phenotypically screened carbon nanoparticles for TNBC cell lines. Results indicated a 
remarkable five-fold improvement (IC50-6.75µM) from the parent  drugs  with  a  combinatorial  
index  < 1  in majority  of  the  TNBC cells.  Multi-compartmental carbon nanoparticles were 
then parametrically assessed based on size, charge (positive/negative/neutral) and chemistry 
(functionalities) to study their likelihood of crossing endocytic barriers from phenotypical 
standpoint in TNBC lines. Interestingly, a  combination  of  clathrin  mediated,  energy  and  
dynamin  dependent  pathways  were predominant  for  sulfonated  nanoparticles,  whereas 
pristine  and phospholipid  particles followed all the investigated endocytic pathways. An  
exactitude  ‘omics’  approach  helps  to  predict  that  phospholipid encapsulated-particles  will  
predominantly  accumulate  in  TNBC  comprising  the  drug ‘cocktail’. Thus, our efforts might 
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CHAPTER 1: INTRODUCTION 
Triple negative breast cancer (TNBC) is categorized by tumors which lack the expression 
of estrogen receptor (ER), progesterone receptor (PR) or HER-2 gene.[1]  The lack of these 
receptors means that TNBC does not respond to the hormonal therapies which are standard in 
clinical practice. TNBC accounts for 10-20% of invasive breast cancers, but plays a large role in 
the breast cancer mortality rate.[2-6]  This is because TNBC is characterized by a poor prognosis 
and a shorter time frame for patient relapse or death. TNBCs often become resistant to 
chemotherapy, making it very difficult to prevent metastases or recurrence.[7]  It is believed that 
recurrent tumors exhibit chemoresistance due to a small surviving population of cancer stem 
cells following initial chemotherapy treatment.  Cancer stem cells have stem-like properties, 
allowing for self renewal and proliferation to form new, chemoresistant tumors.  Advancement in 
TNBC treatment may also be facilitated by utilizing a combination of drugs, which can 
target multiple protein cascades.  
 To fulfill this unmet need for an effective therapy, we propose using a combinatorial 
cocktail of drugs with different target intracellular protein cascades and known individual 
efficiency.  Four different small molecules have been chosen for this study including 
pentoxifylline, niclosamide, nifuroxazide and amonafide.  Pentoxifylline is an FDA approved 
drug and has been shown to block NFkb action, which controls DNA transcription and cell 
survival.[8]  Niclosamide is an FDA approved anthelmintic drug and has been established as a 
highly potent small-molecule inhibitor of the STAT-3 signaling pathway and triple negative 
breast cancer cells.[9-11]  Similarly, nifuroxazide is an FDA approved drug and has been shown to 
effectively inhibit STAT-3 pathway function.[12]  Amonafide (benzisoquinolinedione), an imide 
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derivative of 3-nitro-1, 8-napthalic acid, is currently under phase III clinical trial.[13-15]  
Amonafide is known to be a topoisomerase-II inhibitor.[16] 
 We hypothesize that the combination of these drugs will have a synergistic effect on 
TNBC and will simultaneously suppress drug resistance through distinct mechanisms of action. 
It has been shown that niclosamide inhibits cancer stem like cells, which will prevent recurrence 
of tumor after treatment.[11] Since nifuroxazide is also a STAT-3 inhibitor, a similar effect is 
expected.  Through trials, amonafide has shown a great cytotoxic and antitumor activity.[13-15]  
Pentoxifylline has been shown to increase apoptotic activity in cells in combination with other 
cancer drugs.[17]  Designing a drug formulation using bio-molecularly targeted drugs will more 
effectively treat TNBC and will allow us to reduce off target cytotoxicity.   
 However, combinatorial drug delivery is not trivial and can only successfully be achieved 
through a well-defined nanoparticle platform.[18-20] Design of an ideal nanostructure would allow 
us to encapsulate the therapeutic agents with varying polarity profiles in a highly stable manner 
to avoid systemic dis-integration. Due to the inability of current techniques to envisage which 
patients will be most responsive to these treatments, [21-24]   it is critical to identify tumors likely 
to respond to drugs delivered via nanoparticles providing a better match based on patients’ 
pathophysiology. We hypothesize that assuming a ‘precision’ nanomedicine approach 
can envisage a patient- specific response to a drug based on physiological alterations to 
nanotherapeutics.   
 Internalization of nanoparticles to a cell is typically guided by penetration, 
adhesion, hemifusion and endocytosis.[25-27] Endocytosis is one of the most well-studied cellular 
barriers, involved in several specialized functions.[28-32]   Independent studies indicate 
that endocytotic variations in cancer cells may affect cell surface expression of crucial molecules 
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and significantly impact the cancer-relevant phenotypes, with potential implications for 
interventions to control cancer by modulating nanoparticle surface chemistry and other 
parametric function. Various signaling pathways do persist in the endocytic route and emerging 
evidence ties endocytosis as a whole, or individual proteins to mitosis, apoptosis and cell fate 
determination. Internalization of nanoparticles in cells are often dictated by their size, [33-
35] functionality, [36-38] and surface charge.[39,40] However, the mechanistic understanding of 
nanoparticle internalization is dependent on the stepwise progression of cancer, leading to tumor 
formation and subsequent metastasis, which is complex and not well understood.   
 With this unmet need, our approach follows the field of genetics to predict an 
individual’s response to a drug, based on the histopathological information obtained from 
biopsy. A diagnostic cohort will be generated for stratification of ‘right’ delivery 
platform candidate relying on cancer phenotypes for potentially improved efficacy and reduced 
toxicity.  We parametrically assessed carbon nanoparticles based on their charge and surface 
chemistry through endocytic stratification from pathophysiological differences. Carbon nanodots 
were chosen as a base platform due to its biodegradable nature, ease of large scale production, 
and facile surface characteristics.[41,42] We anticipate that uniting biopsy results with a 
nanomedicine of superior probabilities to cross the endocytic “barrier” to 
deliver combinatorial drug can be proposed.[43-63]   
 Towards this aim, a series of carbon dots were prepared with cationic, anionic or neutral 
surface functionalities. Carbon nanoparticles have shown great potential as drug delivery 
vehicles due to excellent biocompatibility, ease of synthesis and surface modification 
properties.  These particles can easily penetrate cytoplasmic and nuclear membranes, allowing 
for enhanced delivery of the intact drug to tumor sites for more effective treatment compared to 
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free drug.[64-66] Anticancer drugs have been tested in a carbon nanoparticle system both in vitro 
and in vivo with promising results. Our laboratory and others have demonstrated that these 
particles can also be utilized as a contrast probe for imaging various biological processes.[67-
70]  Our results for the first time demonstrated that carbon nanoparticles, as a function of their 
surface charge, behave uniquely in presence of TNBC cells in comparison to non-TNBC 
cells. Although the understanding of pathophysiological contributions of endocytic alterations is 
not robust, we studied the major endocytic routes, i.e. clathrin, lipid-raft mediated, dynamin, and 
energy-dependent pathways. Selective endocytic pathway depending on the TNBC nature of 
breast cancer can be selected and this understanding of surface characteristics and cancer stage-
driven internalization of particles guided us to select the best delivery platforms with optimized 





CHAPTER 2: COMBINATORIAL THERAPY 
 
2.1 MATERIALS AND METHODS 
MATERIALS  
Pentoxifylline was purchased from Sigma-Aldrich (MO, USA) and used without further 
purification. Amonafide was purchased from Santa Cruz Biotechnology (TX, USA). 
Niclosamide and  Nifuroxazide were purchased from A.K.Scientific (Union City, CA, USA).  
Anti-STAT3 and β-actin primary antibodies were purchased from AbCam (Cambridge, MA). 
Secondary HRP-conjugated goat anti-rabbit and HRP-conjugated goat anti-mouse were 
purchased from AbCam (Cambridge, MA). TOPO-II antibody was purchased from Invitrogen 
(Waltham, MA). NF b antibody was purchased from ThermoFisher Scientific (Waltham, MA). 
MTT solution was purchased from Biosynth (Pittsburgh, PA). DMEM and McCoy’s 5a medium 
were purchased from Sigma-Aldrich (MO, USA). RPMI-1640  medium was purchased from 
ATCC (Manassas, VA). VitroGel RGD was purchased from TheWell Bioscience Inc. (Newark, 
NJ). alamarBlue was purchased from Invitrogen (Waltham, MA). 
 
CELL LINES 
 MDA-MB-231 cells were obtained from American Type Culture Collection (ATCC) and 
cultured according to the standard mammalian tissue culture protocols and sterile technique.  
Cells were cultured in DMEM medium supplemented with 1.5 g sodium bicarbonate, 10% FBS 
and 1% penicillin/streptomycin. 
 BT-549 cells were obtained from American Type Culture Collection (ATCC) and 
cultured according to the standard mammalian tissue culture protocols and sterile technique.  
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Cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 0.023 IU/ml insulin 
and 1% penicillin/streptomycin. 
 HCC1806 cells were obtained from American Type Culture Collection (ATCC) and 
cultured according to the standard mammalian tissue culture protocols and sterile technique.  
Cells were cultured in RPMI-1640 medium supplemented with 10% FBS and 1% 
penicillin/streptomycin. 
 HCC1143 cells were obtained from American Type Culture Collection (ATCC) and 
cultured according to the standard mammalian tissue culture protocols and sterile technique.  
Cells were cultured in RPMI-1640 medium supplemented with 10% FBS and 1% 
penicillin/streptomycin. 
 MCF-7 cells were obtained from American Type Culture Collection (ATCC) and 
cultured according to the standard mammalian tissue culture protocols and sterile technique.  
Cells were cultured in DMEM medium supplemented with 1.5 g sodium bicarbonate, 10% FBS 
and 1% penicillin/streptomycin. 
 SkBr3 cells were obtained from American Type Culture Collection (ATCC) and cultured 
according to the standard mammalian tissue culture protocols and sterile technique.  Cells were 
cultured in McCoy’s 5a medium supplemented with 10% FBS and 1% penicillin/streptomycin. 
 
CELL GROWTH INHIBITION OPTIMIZATION WITH MTT ASSAYS  
MDA-MB-231 and MCF-7 cells were seeded at 10,000 cells/well in DMEM with 10% 
FBS and 1% P/S (200 µL/well) in a 96-well plate and incubated at 37 °C and 5% CO2 for 24 
hours. Cell treatments were as follows: PTX – Pentoxifylline, NSL – Niclosamide, NIFU – 
Nifuroxazide, AMF – Amonafide, PTX+NSL, PTX+NIFU, PTX+AMF, NSL+AMF, 
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NIFU+AMF, PTX+NSL+AMF and PTX+NIFU+AMF.  Each treatment of the cells had 
concentrations ranging 12.5 – 50 µM. After treatment, cells were incubated for either 44, 68 or 
92 hours.  After 44, 68 or 92 hours, 20 µL MTT solution (5 mg/mL Thiazolyl Blue Tetrazolium 
Bromide) was added to each well and the plate was incubated for an additional 4 hours.  Media 
was then aspirated from each well and 200 µL dimethyl sulfoxide (DMSO) was added.  The plate 
absorbance was then read at 560 nm wavelength using Gen5 Microplate Reader and Imager 
Software.    
 
CELL GROWTH INHIBITION STUDIES ON ADDITIONAL CELL LINES BY MTT 
ASSAY  
BT-549 cells were seeded at 10,000 cells/well in RPMI-1640 with 10% FBS, 0.023 
IU/mL insulin and 1% P/S, SkBr3 cells were seeded at 10,000 cells per well in McCoy’s 5a with 
10% FBS and 1% P/S, HCC1806 cells were seeded at 10,000 cells per well in RPMI-1640 with 
10% FBS and 1% P/S, and HCC1143 cells were seeded at 10,000 cells per well in RPMI-1640 
with 10% FBS and 1% P/S (200 µL/well) in a 96-well plate and incubated at 37 °C and 5% CO2 
for 24 hours. Cell treatments were as follows: PTX – Pentoxifylline, NIFU – nifuroxazide, AMF 
– Amonafide, PTX+NIFU, PTX+AMF, NIFU+AMF and PTX+NIFU+AMF.  Each treatment of 
the cells had concentrations ranging 12.5 – 50 µM. After treatment, cells were incubated for 44 
hours.  After 44 hours, 20 µL MTT solution (5 mg/mL Thiazolyl Blue Tetrazolium Bromide) 
was added to each well and the plate was incubated for an additional 4 hours.  Media was then 
aspirated from each well and 200 µL DMSO was added.  The plate absorbance was then read at 
560 nm wavelength using Gen5 Microplate Reader and Imager Software.      
PROTEIN ANALYSIS WITH WESTERN BLOT 
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Western blotting was used to examine the expression of pSTAT3, TOPOII, NFkb and 
a housekeeping protein β-actin. 100 mm2 dishes were plated at 5x106 MDA-MB-231 cells per 
dish and treated with the PTX, NIFU, AMF or PTX+NIFU+AMF at concentration of 25 µM 
after 24 hours of cell growth.  After treatment, cells were incubated for 48 hours. Total 
protein content in the cells was extracted using M-PER™ Mammalian Protein Extraction 
Reagent (ThermoFisher Scientific, USA) as recommended in manufacturer’s protocol. The 
concentration of the protein samples was determined by a colorimetric assay using Pierce™ 
BCA Protein Assay Kit (ThermoFisher Scientific, USA). 10 µg of protein extracts from various 
cell treatments were separated by gradient (4-20%) sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and then transferred to a nitrocellulose membrane (Bio-Rad, USA) using a wet 
transfer unit (Bio-Rad, USA). Protein laden membranes were blocked with 5% non-fat milk in 
TBS-Tween buffer for an hour at room temperature, and incubated overnight at 4°C with the 
appropriate primary antibodies; β-actin (1:3000), pSTAT3 (1:3000), NFkb  (1:3000) and Topo-II 
(1:3000). This was followed by incubation with an HRP-conjugated goat anti-mouse or HRP-
conjugated goat anti-rabbit secondary antibody (Thermo Scientific, USA) for an hour and 
subsequent washing in TBST. The blots were developed using Chemiluminescent kit 
(Thermo Scientific) to detect the target protein as per manufacturer’s protocol.  
 
3D CULTURE 
MDA-MB-231 cells were seeded at 100,000 cells per well in a 1:3 dilution of  
VitroGel3D-RGD (TheWell Bioscience, USA) with 50 µL media in a 96-well plate and 
incubated at 37 °C and 5% CO2 for 96 hours. Cell treatments were as follows: PTX – 
Pentoxifylline, NIFU – Nifuroxazide, AMF – Amonafide, PTX+NIFU, PTX+AMF, NIFU+AMF 
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and PTX+NIFU+AMF.  Each treatment of the cells had concentrations ranging 12.5 – 50 µM. 
After treatment, cells were incubated for 44 hours.  After 44 hours, 15 µL alamarBlue® 
(ThermoFisher Scientific, USA) reagent was added to each well and the plate was 
incubated for an additional 4 hours. The plate fluorescence was then read at 570 nm excitation 
and 585 nm emission using Gen5 Microplate Reader and Imager Software.    
 
STATISTICAL ANALYSIS 
Statistical significance of differences between control and samples were evaluated using 
one- way ANOVA using GraphPad Prism with Dunnett or Bonferroni analysis wherever 
applicable. Results were considered statistically significant when the p value was less than 0.05. 
Statistical analysis results were represented as * for p<0.05, ** for p<0.01, *** for p<0.001 and 
**** for p<0.0001.  
 
2.2 RESULTS AND DISCUSSION 
 
OPTIMIZATION 
 In this study, we examined the effect of treatment with a single small molecule, targeting 
one signaling pathway; double combinations of small molecules, targeting two signaling 
pathways; and triple combinations of small molecules, targeting all three of the desired signaling 
pathways. Pentoxifylline targets the NFkb signalling cascade, niclosamide and nifuroxazide 
target the STAT-3 signalling cascade, and amonafide targets the TOPO-II signalling cascade. To 
assess the impact of our various treatments, we utilized MTT assay, testing in a TNBC cell line, 
MDA-MB-231, and a non-TNBC cell line, MCF-7, serving as a control. We tested 3 different 
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concentrations of the drugs: 12.5, 25 and 50 µM. Additionally, we tested 3 different treatment 
time points: 48, 72 and 96 hours. 
 
Figure 1. Brightfield images of MDA-MB-231 cells, plated at 10 x 103 cells/well following 48 hours of treatment at 







Figure 2. Brightfield images of MCF-7 cells, plated at 10 x 103 cells/well following 48 hours of treatment at 50 µM. 






In the Brightfield images shown in Figures 1 and 2, we can see distinct morphological 
changes in both MDA-MB-231 and MCF-7 cells following 48 hours of treatment. In MDA-MB-
231 cells, we observe a large amount of cell death compared to untreated cells. This is also seen 
in MCF-7 cells, but the cell death is not as extensive. The results of these treatments were 
quantified with MTT assay. 
 
 
Figure 3. MTT Assay of MDA-MB-231 and MCF-7 cells at 48 hours of treatment. Cells were plated at 10 x 103 
cells/well at treated at 12.5, 25 or 50 µM. a) MDA-MB-231 single molecule and combinations treatments with NSL, 
b) MCF-7 single molecule and combination treatments with NSL, c) MDA-MB-231 single molecule and 







Figure 3 shows the cell viability of MDA-MB-231 and MCF-7 cells treated with our 
various drug combinations at the 48 hour time point. Here we observe that treatments were 
generally more effective in TNBC cell line, MDA-MB-231. Across both cell lines, we can 
observe that combination treatments work more efficiently than the single molecule treatments 
itself.  In MDA-MB-231 at 25 µM, cell death was about 92% for both triple combination 
treatments, PTX+NSL+AMF and PTX+NIFU+AMF. In MCF-7 cells, we observed 75% and 
84% cell death for triple combination treatments, respectively.  Statistics, as noted in Tables 1 
and 2, show that in both MDA-MB-231 and MCF-7, there was a very significant difference in 
cell viability between PTX treatment alone and PTX treatment in triple combinations. From the 
statistical analysis, we can also see that NIFU is a very effective drug on its own and there is not 
very significant difference in most combination treatments. AMF was found to be a very potent 


























Table 1. Statistical analysis of MDA-MB-231 cells after 48 hours; single molecule treatment compared 
to combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and treated 













50 µM **** **** **** **** **** 
25 µM **** **** **** **** **** 
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50 µM NS NS * 
25 µM NS NS NS 














50 µM NS NS NS NS NS 
25 µM NS * * * ** 





Table 2. Statistical analysis of MCF-7 cells after 48 hours; single molecule treatment compared to 
combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and treated at 













50 µM NS **** **** ** **** 
25 µM NS **** **** **** **** 










50 µM ** **** **** 
25 µM NS **** **** 










50 µM NS NS NS 
25 µM NS NS NS 














50 µM NS NS NS NS NS 
25 µM NS NS * NS * 





 Therapeutic potential of drug and drug combinations generally depends on extent of 
interruption they can introduce in protein cascades of cellular mechanisms and in turn time span 
of treatments. This lead us to examine our experimental and control cells after a longer time 





Figure 4. Brightfield images of MDA-MB-231 cells, plated at 10 x 103 cells/well following 72 hours of treatment at 








Figure 5. Brightfield images of MCF-7 cells, plated at 10 x 103 cells/well following 72 hours of treatment at 50 µM. 






Similar to the brightfield images at 48 hours of treatment, there are very obvious 
morphological changes in both of the treated cell lines (Figures 4 and 5). Overall, there seems to 
be little change in the amount of cell death between 48 and 72 hours. These results were also 
quantified with MTT assay.  
 
 
Figure 6. MTT Assay of MDA-MB-231 and MCF-7 cells at 72 hours of treatment. Cells were plated at 10 x 103 
cells/well at treated at 12.5, 25 or 50 µM. a) MDA-MB-231 single molecule and combinations treatments with NSL, 
b) MCF-7 single molecule and combination treatments with NSL, c) MDA-MB-231 single molecule and 
combination treatments with NIFU, d) MCF-7 single molecule and combination treatments with NIFU. 
 
Figure 6 shows the cell viability of MDA-MB-231 and MCF-7 cells treated with our 
various drug combinations at the 72 hour time point. In both cell lines, we can see a more potent 





produce a similar effect at both 50 and 25 µM. Statistical analysis, shown below in Tables 3 and 
4, for the 72 hour time point showed some interesting differences compared to the 48 hour time 
point. After 72 hours, there are less significant changes between single molecule and 








Table 3. Statistical analysis of MDA-MB-231 cells after 72 hours; single molecule treatment compared 
to combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and 
treated at 12.5, 25 or 50 µM. 
MDA-MB-











50 µM *** **** **** **** **** 
25 µM NS ** NS ** ** 










50 µM NS * * 
25 µM NS NS NS 










50 µM NS NS NS 
25 µM NS NS NS 
12.5 µM NS NS NS 
 
MDA-MB-











50 µM NS NS NS NS NS 
25 µM NS ** ** ** ** 








Table 4. Statistical analysis of MCF-7 cells after 72 hours; single molecule treatment compared to 
combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and treated at 
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25 µM **** **** **** **** **** 
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25 µM NS *** **** 










50 µM NS NS NS 
25 µM NS NS NS 














50 µM NS NS NS NS NS 
25 µM NS NS NS NS NS 





Finally, we examined the morphology of the cells after 96 hours of treatment.  
 
Figure 7. Brightfield images of MDA-MB-231 cells, plated at 10 x 103 cells/well following 96 hours of treatment at 







Figure 8. Brightfield images of MCF-7 cells, plated at 10 x 103 cells/well following 96 hours of treatment at 50 µM. 






After 96 hours, morphology of the cells is similar to 48 and 72 hour time points (Figures 
7 and 8). There is obvious cell death in treated cells compared to control. This is quantified 




Figure 9. MTT Assay of MDA-MB-231 and MCF-7 cells at 96 hours of treatment. Cells were plated at 10 x 103 
cells/well at treated at 12.5, 25 or 50 µM. a) MDA-MB-231 single molecule and combinations treatments with NSL, 
b) MCF-7 single molecule and combination treatments with NSL, c) MDA-MB-231 single molecule and 








Figure 9 shows the cell viability of MDA-MB-231 and MCF-7 cells treated with our 
various drug combinations at the 96 hour time point. At the 96 hour time point, there was 
significant cell death in most treatment combinations. Statistical analysis shows similar results to 
the 72 hour time point (Tables 5 and 6).  
 
  Table 5. Statistical analysis of MDA-MB-231 cells after 96 hours; single molecule treatment compared 
to combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and 
treated at 12.5, 25 or 50 µM. 
MDA-MB-
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25 µM **** **** **** **** **** 
12.5 µM **** **** NS **** **** 
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12.5 µM NS NS NS 
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25 µM NS NS NS 
12.5 µM NS NS NS 
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25 µM NS *** *** *** *** 









Table 6. Statistical analysis of MCF-7 cells after 96 hours; single molecule treatment compared to 
combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and treated at 
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25 µM NS **** **** **** **** 
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SYNERGISTIC EFFECT OF DRUG COMBINATIONS USING IC90/CI SYSTEM  
To assess the combinatorial effect of our drug formulation, we examined combinatorial 
index (CI). We looked at the inhibitory concentration necessary to kill 10% of cells, or IC90. 
This value was chosen because in some cell lines, PTX treatment did not result in greater that 
10% cell death. IC90 values for MDA-MB-231 and MCF-7 cells at 48 hours are shown below 
(Figure 10). We see that only a very low concentration of treatment is needed to achieve this 






Figure 10. IC90 values for MDA-MB-231 and MCF-7 cells after 48 hours of treatment. Cells were plated at 10 x 
103 cells per well. a) IC90 of MDA-MB-231 cells treated with single molecule or combination treatments with NSL, 
b) IC90 of MCF-7 cells treated with single molecule or combination treatments with NSL, c) IC90 of MDA-MB-
231 cells treated with single molecule or combination treatments with NIFU, d) IC90 of MCF-7 cells treated with 







After assessing IC90, these values were used to calculate combinatorial index (CI). A CI 
of less than, equal to, or more than 1 indicates synergic, additive or antagonistic effect, 
respectively. Synergism was not observed in MDA-MB-231, and was only seen in two 
combinations in MCF-7 at 48 hours (Table 7).  
Table 7. Utilizing calculated IC90 values, we determine the combinatorial index in MDA-MB-231 and MCF-7 cells 
after 48 hours of treatment.  
48 hours MDA-MB-231 MCF-7 
PTX+NSL 1.6 1.2 
PTX+NIFU 1.7 1.3 
PTX+AMF 1.5 0.9 
NSL+AMF 1.7 0.9 
NIFU+AMF 1.6 1.4 
PTX+NSL+AMF 2.1 1.5 
PTX+NIFU+AMF 2.3 1.4 
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At 72 hours, we can see that the IC90 values are a not as consistent as in the 48 hour 
treatment. There is more variation in the concentration necessary, possibly due to the longer 
incubation time (Figure 11).  
 
Figure 11. IC90 values for MDA-MB-231 and MCF-7 cells after 72 hours of treatment. Cells were plated at 10 x 
103 cells per well. a) IC90 of MDA-MB-231 cells treated with single molecule or combination treatments with NSL, 
b) IC90 of MCF-7 cells treated with single molecule or combination treatments with NSL, c) IC90 of MDA-MB-
231 cells treated with single molecule or combination treatments with NIFU, d) IC90 of MCF-7 cells treated with 






After 72 hours, CI values increase, showing a more antagonistic effect in both cell lines. 
This is shown below in Table 8. 
 
Table 8. Utilizing calculated IC90 values, we determine the combinatorial index in MDA-MB-231 and MCF-7 cells 
after 72 hours of treatment.  
72 hours MDA-MB-231 MCF-7 
PTX+NSL 1.8 1.4 
PTX+NIFU 1.7 1.0 
PTX+AMF 4.4 1.3 
NSL+AMF 1.2 1.6 
NIFU+AMF 2.1 1.7 
PTX+NSL+AMF 1.9 1.9 
PTX+NIFU+AMF 1.9 1.5 
 
 
At 96 hours, we again see varied concentration values for the IC90 of MDA-MB-231 
cells. The necessary value of PTX alone is much greater at this time point than either of the 
previous two. Necessary concentrations are very low in MCF-7 cells for all combinations of 




Figure 12. IC90 values for MDA-MB-231 and MCF-7 cells after 96 hours of treatment. Cells were plated at 10 x 
103 cells per well. a) IC90 of MDA-MB-231 cells treated with single molecule or combination treatments with NSL, 
b) IC90 of MCF-7 cells treated with single molecule or combination treatments with NSL, c) IC90 of MDA-MB-
231 cells treated with single molecule or combination treatments with NIFU, d) IC90 of MCF-7 cells treated with 







At 96 hours, CI values decrease relative to the 72 hour time point. Additionally, CI 
indicates some synergism in the PTX+NIFU combination in MDA-MB-231 (Table 9).  
 
Table 9. Utilizing calculated IC90 values, we determine the combinatorial index in MDA-MB-231 and MCF-7 cells 
after 96 hours of treatment.  
96 hours MDA-MB-231 MCF-7 
PTX+NSL 1.2 2.7 
PTX+NIFU 0.9 2.2 
PTX+AMF 3.0 1.9 
NSL+AMF 1.2 1.6 
NIFU+AMF 1.3 1.5 
PTX+NSL+AMF 1.4 2.8 
PTX+NIFU+AMF 1.6 2.7 
 
 
Based on the cell viability data and CI data obtained, we decided to proceed testing with a  
48 hour treatment time, and to omit NSL from our treatment regimen. As there were no major 
differences in cell viability in NSL vs. NIFU treatments, and there was some indication of 
synergism in NIFU treatments, we chose to use NIFU as our STAT-3 inhibitor. We decided to 
proceed with a 48 hour treatment time as there was no indication that treating for a longer period 
of time resulted in greater viability. 
 
ADDITIONAL CELL LINES FOR CELL TOXICITY STUDY  
 After the above optimizations, we tested our treatment 48 hour treatment time with 
various combinations of Pentoxifylline, Nifuroxazide and Amonafide in an additional TNBC cell 




Figure 13. Brightfield images of BT-549 cells, plated at 10 x 103 cells/well following 48 hours of treatment at 50 









Figure 14. Brightfield images of BT-549 cells, plated at 10 x 103 cells/well following 48 hours of treatment at 50 
µM. a) Control cells, b-d) single molecule treatments, e-g) double combination treatments, h) triple combination 
treatment. 
 
The above Brightfield images show morphological changes after 48 hours of treatment 
(Figures 13 and 14). We can see that the greatest change in cell density in BT-549 is in our triple 
combination treatment. In SKBR3, we can see that all of our treatments are fairly effective. 







Figure 15. MTT Assay of BT549 and SKBR cells at 48 hours of treatment. Cells were plated at 10 x 103 cells/well 
at treated at 12.5, 25 or 50 µM, a) BT549 single molecule and combination treatments, b) SKBR3 single molecule 






We can see that our combination treatments were very effective at 50 µM in BT-549. Cell 
death was about 93% for the triple combination treatment. In SKBR3 cells, treatment was fairly 
effective for all treatments and combinations (Figure 15). Statistics in Tables 10 and 11 show a 
very strong significance between testing with PTX alone and PTX in combination with our other 














Table 10. Statistical analysis of BT549 cells after 48 hours; single molecule treatment compared to 
combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and treated at 
12.5, 25 or 50 µM. 






50 µM **** **** **** 
25 µM * NS **** 
12.5 µM *** ** **** 
 






50 µM NS * NS 
25 µM NS * ** 
12.5 µM NS NS * 
 






50 µM NS NS NS 
25 µM NS *** **** 









Table 11. Statistical analysis of SKBR3 cells after 48 hours; single molecule treatment compared to 
combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and treated at 
12.5, 25 or 50 µM. 






50 µM **** *** **** 
25 µM ** * *** 
12.5 µM **** *** **** 
 






50 µM NS NS NS 
25 µM NS NS * 
12.5 µM NS NS NS 
 






50 µM NS NS * 
25 µM NS NS * 





Figure 16. IC90 values for B549 and SKBR3 cells after 48 hours of treatment. Cells were plated at 10 x 103 cells 
per well. a) IC90 of BT549 cells treated with single molecule or combination treatments, b) IC90 of SKBR3 cells 
treated with single molecule or combination treatments. 
 
When looking at IC90 for these two cell lines, we can see that a lower concentration is 
necessary to reach this level of cell death when using the triple combination treatment compared 
to individual small molecules in BT549 cells (Figure 16). When looking at CI index for this cell 
line, we can see a synergistic effect in both the PTX+NIFU treatment and the triple combination 
treatment. While very low concentrations are necessary to reach IC90 values in SKBR3, there is 
no synergism observed (Table 12).  
 
Table 12. Utilizing calculated IC90 values, we determine the combinatorial index in BT549 and SKBR3 cells after 
48 hours of treatment.  
 BT549 SKBR3 
PTX+NIFU 0.9 1.6 
PTX+AMF 1.3 1.7 
NIFU+AMF 1.11 1.9 






 Finally, we tested our optimized drug combination in 2 additional TNBC cell lines, 
HCC1806 and HCC1143. We can see that at both the 50 and 25 µM concentrations, there is a 
very high level of cell death for our triple combination treatments in HCC1806 (97%) and 
HCC1143( 91%). We can see that at these concentrations, treatment efficacy is very similar. The 
12.5 µM treatment does not induce such a great effect in either cell line (Figure 17). Statistics 
show a very significant change in treatment with PTX alone vs. PTX in combination with our 
other drugs, as previously seen. Additionally, we can see that there is a significant difference in 
using NIFU alone vs. NIFU in the triple combination treatment in HCC1806, which is different 





Figure 17. MTT Assay of HCC1806 and HCC1143 cells at 48 hours of treatment. Cells were plated at 10 x 103 
cells/well at treated at 12.5, 25 or 50 µM, a) HCC1806 single molecule and combination treatments, b) HCC1143 





























Table 13. Statistical analysis of HCC1806 cells after 48 hours; single molecule treatment compared to 
combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and treated at 
12.5, 25 or 50 µM. 






50 µM **** **** **** 
25 µM *** **** **** 
12.5 µM *** **** **** 
 






50 µM NS *** *** 
25 µM NS **** **** 
12.5 µM *** **** **** 
 






50 µM NS NS NS 
25 µM NS NS NS 
12.5 µM NS ** *** 
 
Table 14. Statistical analysis of HCC1143 cells after 48 hours; single molecule treatment compared to 
combination treatments with that single molecule. Cells were plated at 10 x 103 cells/well and treated at 
12.5, 25 or 50 µM. 






50 µM **** **** **** 
25 µM **** *** **** 
12.5 µM **** *** **** 
 






50 µM NS NS NS 
25 µM NS NS * 
12.5 µM NS NS NS 
 






50 µM NS * * 
25 µM NS ** *** 







Figure 18. IC90 values for HCC1806 and HCC1143 cells after 48 hours of treatment. Cells were plated at 10 x 103 
cells per well. a) IC90 of HCC1806 cells treated with single molecule or combination treatments, b) IC90 of 
HCC1143 cells treated with single molecule or combination treatments. 
 
When looking at IC90 values for these cell lines, we can see that testing in combination 
makes a difference in necessary concentration compared to treatment with single molecules 
(Figure 18). Combinatorial index shows us that there is synergism in all combination treatments 
in HCC1806, and  synergism in PTX+NIFU and PTX+AMF in HCC1143 (Table 15).  
 
Table 15. Utilizing calculated IC90 values, we determine the combinatorial index in HCC1806 and HCC143 cells 
after 48 hours of treatment.  
 HCC1806 HCC1143 
PTX+NIFU 0.5 0.9 
PTX+AMF 0.9 1.0 
NIFU+AMF 0.7 1.5 







CELL TOXICITY STUDY IN 3D CULTURE  
 Following optimization and extensive testing in 2D models, we aimed to expand our 
therapeutic combination to a 3D culture model. A 3D culture system would allow us to assess an 
effect more similar to that which we may see in the human body. Utilizing a hydrogel system by 
The Well Bioscience, we tested our treatment on 3D culture of MDA-MB-231 cells. 
 
Figure 19. alamarBlue Assay of MDA-MB-231 cells at 48 hours of treatment. Cells were plated at 10 x 104 
cells/well at treated at 12.5, 25 or 50 µM,  
  
 Statistical analysis of our 3D model shows that there was a statistically significant 
difference between treating with PTX alone versus PTX+AMF or PTX+NIFU+AMF at 25 and 
50 µM. Additionally, we saw a statistically significant difference between NIFU alone and NIFU 
in triple combination at 25 µM.  These results indicate that the triple combination cocktail does 
have a significant impact in treating this line of TNBC (Figure 19 and Table 16).  
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Table 16. Statistical analysis of MDA-MB-231 cells after 48 hours; single molecule treatment compared to 
combination treatments with that single molecule. Cells were plated at 10 x 104 cells/well in VitroGel RGD 









50 µM NS ** ** 
25 µM NS ** *** 










50 µM NS NS NS 
25 µM NS NS * 










50 µM NS NS NS 
25 µM NS NS NS 
12.5 µM NS NS NS 




ASSESSING PROTEIN EXPRESSION LEVELS WITH WESTERN BLOT  
In order to assess if our targeted therapy was functioning through the hypothesized 
mechanisms of action, we used western blot to look at protein expression following treatment. 
We examined protein expression in MDA-MB-231 cells treated at 25 µM for 48 hours. Thus far, 
we have assessed the protein expression response in TOPO-II and NFkb signalling pathways. 
Treatments were as follows: 1 – PTX+NIFU+AMF, 2 – AMF, 3 – NIFU, 4 – PTX, C – Control. 
Each treatment for each of these pathways was compared to a housekeeping protein, β-actin. 
As we can see in Figure 20, NFkb protein expression decreases to about 0.6 when treated 
with PTX and about 0.55 when treated with our triple combination cocktail. This decrease shows 
that PTX is working to inhibit the NFkb pathway, as we hypothesized. Similarly, there is a 
decrease in TOPO-II expression to about 0.6 in AMF treated samples, and a decrease to about 




Figure 20. Protein expression data from MDA-MB-231 cells. Cells were treated for 48 hours at 25 µM. a) Western 










 From this study, we derived an optimized formulation for TNBC treatment. This cocktail 
was comprised of PTX, NIFU and AMF, drugs which function through inhibiting the NFkb, 
STAT3 and TOPO-II pathways, respectively. We found an effective treatment range, resulting in 
95% cell death or greater, in some cases. This is a relevant result because we often see therapies 
fail in TNBCs due to their distinct molecular phenotype. It is significant to find a treatment 
combination that works as well in TNBCs as it would in another breast cancer subtype. 
Additionally, when examining combinatorial index, we assessed a synergistic effect in some 
TNBC cell lines, showing that our combination treatment enhances the therapeutic efficacy of 
our single molecules.  
 Testing our drug cocktail in 3D culture models showed potential for an effective 
treatment. At the 50 µM concentration, we observed over 60% cell death. Further testing in 
additional cell lines will need to be done to completely assess the efficacy of the drug cocktail in 
3D models.  
 Finally, we examined protein expression as effected by our therapeutic combination. We 
observed a reduction in expression in NFkb when treated with PTX and our triple combination 
treatment, as well as a reduction in TOPO-II when treated with AMF and the triple combination 
treatment. We will assess STAT-3 protein expression in the future to obtain a complete picture of 




CHAPTER 3: EFFECT OF CARBON NANONSURFACE ON COMBINATORIAL 
THERAPY FOR TNBC   
 
3.1 MATERIALS AND METHODS 
MATERIALS 
Sucrose, Poly(ethylene glycol) (PEG, average Mn = 400, Mn = 10,000 and Mn = 
20,000), Polyethylenimine, branched (PEI, average 
Mw ≈ 25,000), Sodium azide (NaN3, ≥99.5%), Nystatin, 2-Deoxy-D-Glucose (DOG, ≥98%), 
Pentoxifylline were purchased from Sigma-Aldrich (MO, USA) and used without further 
purification. Polyethylene glycol phosphate (PO4-, Mw=5000) was purchased 
from Chemicell (Berlin, Germany). Methoxy PEG Thiol (SH, ≥97%, Mw= 20,000) was 
purchased from JenKem Tech. (TX, USA). Polyethylene glycol monomethyl 
ether mesylate (SO3H, Mw=5000), Chlorpromazine (CPM, 97%), Amonafide were purchased 
from Santa Cruz Biotechnology (TX, USA). Nifuroxazide was purchased 
from A.K.Scientific (Union City, CA, USA). Lecithin was purchased from Coatsome, NOF 
America Corporation, CA, USA. Dynasore (>99%) was purchased from Fisher Scientific (PA, 
USA). The 0.2 µM and 0.45 µM filters (Millex, Merck Millipore Ltd., Tullagreen, Carrigtwohill, 
County Cork, Ireland) were used wherever applicable.   
 
CELL LINES 
HCC1806 is a human breast cancer cell line characterized by lack of estrogen and 
progesterone receptor and no her2/neu expression. The tumor the cell line was isolated from was 
classified as TNM Stage IIB. HCC1806 cells were obtained from American Type Culture 
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Collection (ATCC) and cultured according to the standard mammalian tissue culture protocols 
and sterile technique.  Cells were cultured in RPMI-1640 medium supplemented with 10% FBS 
and 1% penicillin/streptomycin. 
 
PREPARATION OF PRISTINE CNPS 
Pristine CNPs were prepared by dissolving 250 mg of agave nectar in 2 ml 
of nanopure water (0.2 µM, 18 MΩ·cm). Then the aqueous solution was heated on a hot plate at 
270 °C for roughly 30 mins and re-suspended in 4 ml of nanopure water. Followed by 20 min 
probe sonication (Q700TM, Qsonica Sonicators, CT, USA) (Amp:1, On: 2 sec, Off: 1 sec), the 
solution was passed through a syringe filter with a 0.2 µm pore size (Millex®, Merck Millipore 
Ltd., County Cork, Ireland) prior to use.   
 
PREPARATION OF CNPS BY PRE-PASSIVATION 
A mixture of agave nectar and polymer (PEGylated CNPs, CNP PO4, CNP SO3H, CNP 
SH) was taken in glass sample vial of 20 mL capacity. To this, nanopure water was added 
and the solution was mixed well to form a homogenous mixture. The concentration ratio of 
agave nectar to polymeric passivating agent was maintained at 1:1 (w/w). For the nucleation 
process, a hot plate surface was maintained at 270 °C while glass vials were kept un-capped to 
allow the slow evaporation of water. The temperature was maintained for around 30 mins, which 
led to a generation of brownish to black mass (varies with passivating agent). The reaction 
mixture changed color from light yellow to dark brown to black along the course of the heating 
process. The as-synthesized particle mass was suspended in 4 mL of nanopure water followed by 
20 min probe-sonication (Q700TM, Qsonica Sonicators, CT, USA) (Amp: 1, on: 2 sec, off: 1 sec). 
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Sonicated suspension was centrifuged at 12000 g for 20 min, followed by collecting the 
supernatant by filtering through a 0.22 µm syringe filter.   
 
PREPARATION OF CNPS BY POST PASSIVATION 
To make CNP-PEI, 10 µL of branched PEI solution (1mg/10µL) were added to 1 mg of 
CNPs. After vortexed and left at room temperature for 30 mins, the solution was centrifuged for 
30 min at 75,000 rpm at 4 °C (OptimaTM MAX-XP Ultracentrifuge, Beckman-Coulter, CA, USA) 
to remove the suspension. The collected pellet was then redispersed in nanopure water and 
probe-sonicated for 2 mins (Amp: 1, On: 2 sec, Off: 1 sec). All CNP formulations were made 
same concentration (5mg/ml) before using for the study. Similar techniques were adopted for the 
preparation of CNP PolyLys.  
 
PHYSICOCHEMICAL CHARACTERIZATION 
Hydrodynamic diameters and zeta potential of CNPs were determined by a 
Malvern Zetasizer Nano ZS90 (Malvern Instruments Ltd., Worcestershire, UK) in hydrated state. 
The averaged hydrodynamic diameter was obtained from the peak values of the intensity-
weighted distribution with n≥3 and results were reported as mean ± standard 
deviation. Micrographs of transmission electron microscopy (TEM) was collected by JEOL 2010 
LaB6 (JEOL Ltd., Tokyo, Japan) at an acceleration voltage of 200 kV. Samples were deposited 
on 200-mesh Quantifoil holey carbon grids (Structure Probe, Inc., PA, USA) to visualize their 
anhydrous sizes and morphology. Ultraviolet-visible (UV-Vis) absorbance of C3 and that of β-
carotene were recorded via GENESYS 10S UV-Vis Spectrophotometer (Thermo Scientific, MA, 
USA). Absorbance spectra were collected at an interval of 1 nm from 250-900 nm. For FT-IR 
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studies, an aqueous suspension of the CNP-Tri Comb was dried onto a MirrIR IR-reflective glass 
slides (Kelvey Technologies, Chesterland, Ohio, USA) for Fourier Transform Infrared (FT-IR) 
measurements using a Nicolet Nexus 670 FT-IR (Fredrick Seitz Material Research Laboratories 
(FSMRL), Urbana, Illinois, USA). For each measurement 100 x 100 µm images were collected 
at 1 cm-1 spectra resolution with 64 scans per pixel and a 25 x 25 µm pixel size and individual 
spectra were corrected for atmospheric contributions.    
 
INHIBITOR STUDIES  
HCC1806 cells (105) were plated in 96 well plates. Cells were grown for 24h before 
being incubated with different endocytic inhibitors. Inhibitor formulations were made with 
reconstituted medium having sodium azide, DOG (deoxyglucose), CPM (chlorpromazine), 
Nystatin and Dynasore at a concentration of 10 µM, 50 µM, 28 µM, 180 nM and 80 µM, 
respectively, which were used as described in some previous reports [1,2]. Cells were incubated 
with inhibitors for 1h at ambient condition. Inhibitors were then replaced with CNPs suspensions 
in reconstituted medium at concentrations of 5% (v/v). All the treatments were performed in 
triplicate. Cells that had only inhibitor treatments were considered as negative controls whereas 
cells treated with only CNP formulations without any pre-inhibitor treatment were used as 
positive controls. The cytotoxic effect of CNPs were investigated with a 3-(4,5-dime 
thylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich, MO, USA). 
Cells were further grown for 44 h and at the end of incubation, a 20 µL (5 mg/mL) of MTT 
solution was added to each well and cells were further incubated for another 4.5 h. After 
incubation, media were aspirated and 200 µL of dimethyl sulfoxide (DMSO, ≥ 99%, 
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MP Biomedicals, USA) was added to dissolve formazan crystals. Absorption of the samples was 
determined by Synergy HT (BioTek, USA) with a reference wavelength of 592 nm.  
% Cell viability = [{(A592 treated cells) − (A592 background)} / {(A592 untreated cells) − 
(A592 background)}] x 100  
 
ENDOCYTIC BLOCKERS TO DECREASE CELL INTERNALIZATION OF CNPS 
Response to cellular entry of CNPs against endocytic blockers were studied by fold 
decrease in cell death or increase in cell viability. It measures how the cell viability values for 
different CNP formulations, changed with/without the presence of inhibitors. The values were 
calculated by the following formula:  
Fold increase in Cell viability = ((Cell viability of CNP in presence of inhibitor – Cell viability 
of CNP in absence of inhibitors) / Cell Viability of CNP in absence of inhibitors)  
 
STATISTICAL ANALYSIS 
Statistical analysis on various biological results was carried out by using one-way 
ANOVA method. CNP Pristine was treated as control and compared to other CNP formulations. 
Fold increase for the nanoparticle formulations was plotted as mean values ± standard deviation, 
n = 3. Statistical analysis results were represented as * for p<0.05, ** for p<0.01, *** for 
p<0.001 and **** for p<0.0001.  
 
CNP-DRUG FORMULATIONS 
We used three commercial drugs, Amonafide (AMF), Pentoxifylline (PTX) 
and Nifuroxazide (NIFU) wherein they were used to prepare CNP-drug formulations (CNP-
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AMF, CNP-PTX, and CNP-NIFU) along with one formulation having CNP and all the drugs 
used (CNP-Triple).   
  
CNP-AMF FORMULATION   
Firstly, an empty 20ml vial was taken and its weight was noted (w1). We then took 
212mg of sucrose and 0.2mg of AMF in the 20ml vial and recorded the weight again (w2). After 
that, 950µL of water and 50µL of DMSO was added to the 20ml vial, following which 
microwave treatment was done. For microwave treatment, P2 cycle (200W) was applied for 5 
minutes, 5 cycles until the solution evaporated. After this, P10 cycle (1200W) was applied for 2 
minutes, 2 cycles resulting in deposition of char in the vial, and after cooling it at room 
temperature, its weight was recorded. (w3) This char was broken into small pieces using a 
spatula, and 4ml of autoclaved water was added, followed by 20 min probe-sonication 
(Q700TM, Qsonica Sonicators, CT, USA) (Amp: 1, on: 2 sec, off: 1 sec). Sonicated suspension 
was centrifuged at 3000rpm for 30 min, followed by collecting the supernatant by filtering 
through a 0.22 µm syringe filter. The pellets were re-suspended in water and added to the charred 
vial, and let to dry in heat oven overnight, and weight was obtained. (w4)  
 
CNP-PTX FORMULATION 
Similar procedure was adopted for CNP-PTX as CNP-AMF, however, the starting 
amount of sucrose and PTX was 695mg and 0.7mg respectively  
 
CNP-NIF FORMULATION   
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Similar procedure was adopted for CNP-NIFU as CNP-AMF, however, the starting 
amount of sucrose and PTX was 695mg and 0.7mg respectively.  
 
CNP-Tri Comb FORMULATION   
Similar procedure was adopted for CNP-Triple as CNP-AMF, however, the starting 
amount of sucrose, AMF, PTX and NIFU was 1594mg, 0.2mg, 0.7mg and 0.7mg respectively.  
Furthermore, just bare CNPs were prepared using a similar procedure as CNP-AMF, however no 
drug was used and starting amount of sucrose was 1594mg.  
 
MTT ASSAY 
HCC1806 cells were seeded at 10,000 cells/well in RPMI-1640 medium (200 µL/well) in 
a 96-well plate and incubated at 37 °C and 5% CO2 for 24 hours.  Cell treatments were as 
follows: CNP = Carbon nanoparticle, CNP-Am = CNP loaded with Amonafide, CNP-Nif = CNP 
loaded with Nifuroxazide, CNP-PTX = CNP loaded with Pentoxifylline, CNP-Tri = CNP loaded 
with Am + Nif + PTX, Am = Amonafide in water, Am-D = Amonafide in DMSO, Nif = 
Nifuroxazide in water, Nif-D = Nifuroxazide in DMSO, PTX = Pentoxifylline in water, PTX-D 
= Pentoxifylline in DMSO. Each treatment of the cells had concentrations ranging from 1.25 to 
20 lM for Am, 4–70 lM for Nif and PTX in water, DMSO or as loaded in CNP particles.After 
treatment, cells were incubated for 44 hours.  After 44 hours, 20 µL MTT solution (5 mg/mL 
Thiazolyl Blue Tetrazolium Bromide) was added to each well and the plate was incubated for an 
additional 4 hours.  Media was then aspirated from each well and 200 µL DMSO was added.  
The plate absorbance was then read at 560 nm wavelength using Gen5 Microplate Reader and 
Imager Software.    
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PROTEIN EXTRACTION AND WESTERN BLOTTING 
Western blotting was used to examine the expression of pSTAT3 and 
a housekeeping protein β-actin. 100 mm2 dishes were plated at 1x106 cells per dish and treated 
with the previously mentioned drug formulations at concentration of 10 µM of CNP-Am and 35 
of CNP-Nif and CNP-PTX and same concentration incorporated in CNP-Tri Comb after 24 
hours of cell growth.  After treatment, cells were incubated for 48 hours. Total protein content in 
the cells was extracted using Minute™ Total Protein Extraction Kit (Invent Biotechnologies, 
USA) as recommended in manufacturer’s protocol. The concentration of the protein samples was 
determined by a colorimetric assay using Pierce™ BCA Protein Assay Kit 
(ThermoFisher Scientific, USA). A 15 µg of protein extracts from various cell treatments were 
separated by gradient (4-20%) sodium dodecyl sulfate polyacrylamide gel electrophoresis and 
then transferred to a nitrocellulose membrane (Bio-Rad, USA) using a wet transfer unit 
(company name). Protein laden membranes were blocked with 2.5% BSA in TBS-Tween buffer 
(0.12 M Tris-base, 1.5 M NaCl, 0.1% Tween 20) for an hour at room temperature, and incubated 
overnight at 4°C with the appropriate primary antibodies; β-actin (1:3000) and pSTAT3 
(1:3000). This was followed by incubation with an HRP-conjugated goat anti-mouse secondary 
antibody (Thermo Scientific, USA) for an hour and subsequent washing in TBST. The blots were 
developed using Chemiluminescent kit (Thermo Scientific) to detect the target protein as per 
manufacturer’s protocol.  
 
ANIMAL STUDIES 
Advanced 3D cell culture techniques are known to mimic some of the aspects of the in 
vivo tumor environment but still, lack in the complexity found in vivo. Thus, to make a logical 
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transition, after optimizing treatment strategies in vitro, it had to be established in animal models. 
The experimental protocol was approved by the Institutional Animal Care and Use Committee 
(IACUC), University of Illinois, Urbana–Champaign, and satisfied all University and National 
Institutes of Health (NIH) rules for the humane use of laboratory animals. All the animal 
experiments were carried out in accordance with the approved guidelines.   
To evaluate the efficacy of triple drug combination loaded on CNPs in TNBCs, tumor regression 
experiments were performed in xenograft nude animal models. Experiment was designed to 
minimize the use of animals. In order to detect at least 20% difference in tumor size, we decided 
to generate 4 tumors per animal as 3 mice per group. Athymic mice were bought from Charles 
River Laboratories International, Inc. USA. Upon arrival, athymic mice were allowed one week 
for acclimation in animal facility. Animals were single-cage housed and had free access to food 
and water. Animals were housed in Carl R. Woese Institute for Genomic Biology, university of 
Illinois at Urbana-Champaign.  
 
INJECTION OF HCC-1806 IN FLANKS OF ATYHYMIC MICE  
Animals were anesthetized with isoflurane before injecting the HCC 1806 cells. Cells 
were suspended in matrigel (33%, v/v) and injected using an one mL insulin syringe tipped with 
a 26 gauge 1/2′ ′ long needle. 5 × 106 HCC 1806 cells suspended in 
100 µL of matrigel:buffer mixture were injected into four sites on the flank of each mouse. Mice 
were monitored during recovery from the anesthesia and placed in recommended facility for 
allowing the tumor growth. Tumors were grown on the on the cell injection sites with 100% 
success rate. In the time frame of completing the experiment, grown tumors showed no 
significant discomfort to the mice. Mice daily were followed daily for signs of discomfort and 
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any significant behavior change. Mice body weight was measured every 2nd day. Any change in 
physiological function or abnormal behavior including shortness of breath, unsteady gait, 
abnormal eating behavior, physical abnormalities, rough hair coat due to lack of grooming, or 
lethargy were not reported during experiment. Criteria for interventions were set up as animal 
body weight drop by 20% or tumor increase to 17 mm × 17 mm, which was never reached 
during experiment. Tumor size was determined by measuring the length and width of the tumor 
using caliper and then calculating the tumor volume via formulae.  
Tumor volume = length2 × width/2  
 
TREATMENT OF TUMORS  
Animals were followed till tumors grew to a minimum of 5 mm × 5 mm before starting 
the treatment protocol. CNP-Tri Comb was injected to tumors intratumorally (n= 12 tumor) of 
animals (three animals) post anesthesia with isoflurane-oxygen mixture with 3–4% isoflurane 
gas from a vaporizer. A second tube was used to remove carbon dioxide and excess of anesthetic. 
All the personnel involved wore protective lab coats, face masks, sterile gloves during 
experimental procedures. A total of 60 µ L formulation was injected to each tumor after every 48 
hours including 0, 2, 4 and 6th day after first injection and followed for tumor growth regression.  
 
3.2 RESULTS AND DISCUSSION 
PHYSICO-CHEMICAL CHARACTERIZATION  
 Figure 21 shows the overlaid hydrodynamic diameters of as-synthesized nanoparticles 
(<50 nm) while the size did not change aftr drug encapsulation. Anionic CNPs 
exhibited an electrophoretic potential of −30 ± 5 mv to −20 ± 2 mv after being passivated with 
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the anionic and neutral molecules, whereas decrease in surface charge potential (+10 
± 2 mv) for cationic-molecule passivated CNPs confirm their successful surface chemistry. 
Anhydrous particles were studied by transmission electron microscopy (TEM). A representative 
TEM of combinatorially encapsulated CNPs showed a distribution of sizes to be 20 ± 5 nm (Fig. 
2C), slightly smaller than its hydrodynamic size. The loss of hydration layer 
around surface coating while preparing TEM samples likely accounts for the slight decrease in 
size. The FT-IR spectrum of CNP-Tri Comb displayed spectra of both the carbon core as well as 
the drug molecules which were passivated onto it. It exhibited broad peaks for –O-H and –N-H 
centering on 3300 cm-1 and 2900 cm-1, along with asymmetric stretching due to the presence of 
methyl functionalities (nCH3) at 2840 cm-1 and methylene stretching band (nCH2) at 2760 cm-1. 
It also exhibited strong peaks at around 2200cm-1 (nCNO), 2090cm-1 (nC-N) and 1710 cm-
1 (nC=N) which could be due to the passivated drug molecule, PTX. We also observed peaks at 
1780 cm-1 (nC=O), 1450cm-1 (nNO2) and also around 1140 cm-1 (nC-O-C), which is presumably 
due to the presence of the furan ring present in the drug molecules, nifuroxazide. Presence of a 
tertiary amine group (nCN) in amonafide is observed in the FT-IR spectra of the triple drug 




Figure 21. Schematic representation of CNPs, their plausible mechanism of cellular entry, and conceptual cartoon 
behind co-inhibition of NFkb , Topo-II and STAT-3. A) Synthetic pathway to combinatorially loaded CNPs and 
schematic representation of CNPs entering TNBC through endocytosis pathways. B) Chemical structures of three 
repurposed drug molecules, for inhibition of NFkb , Topo-II and STAT-3. (C-D) Transmission electron microscope 
(TEM) images of a representative phospholipid-coated carbon nanoparticles before and after loading, respectively, 









ENZYMATIC DEGRADATION OF CNP BY HUMAN MYELOPEROXIDASE (hMPO)  
Enzymatic degradation of CNPs were confirmed by exposing the samples in presence of 
human myeloperoxidase (hMPO) enzyme. Raman spectra of the CNP as treated 
with hMPO monitored by the change in the Raman intensity over a week. The sample with no 
enzyme treatment was taken as control. The enzymatic degradation can be inferred from the loss 
of the intensity in the D and G bands. Four freeze dried CNP samples were dispersed in DPBS 
with the concentration of 10 mg.ml-1 containing 200 mM of hydrogen peroxide. Then the 
samples were treated with 100 µg of hMPO with activity >50 units.mg−1 at 37 °C except for one 
sample which was taken as control. The activity of the enzyme was impeded at 4 °C after 
specified time points. These samples were dried and further characterized by Raman 




To inspect different endocytic mechanisms utilized by pristine CNP and passivated 
CNPs, pharmacological inhibitors were used. These small molecule inhibitors were selected in 
such a way that they did not exert any significant toxic effect in a short period of incubations. 
Furthermore, they were also not supposed to affect the actin cytoskeleton after the 
treatment. [38,39] The essence of using these inhibitors to probe into the uptake mechanisms is that 
each inhibitor would only block a specific endocytic pathway of interest and consequently CNPs 
internalizing the cells via that pathway. This would in turn decrease the cellular internalization 
and subsequently increase the cell viability. A mixture of sodium azide (NaN3) and 2-
deoxyglucose (DOG), were used to inhibit glycogenosis and cellular respiration 
63 
 
respectively, via energy dependent uptake. [40,41,42] Chlorpromazine (CPM), was used to probe 
into the clathrin dependant entry, as it is known to reduce the formation of clathrin-coated pits 
due to reversible translocation of clathrin and its adapter proteins from plasma membrane to 
intracellular vesicles. [43,44,45] Dynasore has been used to understand the inhibition of dynamin 
(GTPase) dependency in endocytosis of cells. [46, 47] Finally, nystatin, a sterol-binding agent, 
which dismantles caveolae and cholesterol in the membrane, has been employed to 
study clathrin-independent inhibition of endocytosis. [48, 49] Fold-increase calculations were 
performed relative to the cell-viability measurements obtained for different CNP formulations in 
the presence and absence of inhibitors. The following equation was used to calculate the fold-
increase values from the cell-viability measurements.  
Fold-increase in cell viability = ((Cell viability of CNP in presence of inhibitor – Cell viability of 
CNP in absence of inhibitor)/ Cell viability of CNP in absence of inhibitor.   
To investigate the mechanisms of entry, [50, 51] HCC-1806 cells were grown 24hrs 
(10*10^3 cells/well, 96 well plate), were incubated with different inhibitors for 1h (Table 17) 




Table 17. Inhibitors and their treatment conditions for achieving endocytic inhibition by defined working 
mechanism. 
 
All the results obtained from inhibitor studies in terms of cell viability (Figure 22) were 
converted to fold increase values (Figure 23). A mean fold-increase value greater than or equal to 
1.30 was considered to have significant uptake inhibition and suggested it to be the predominant 
internalization pathway as these fold-increase value would consequently lie on a higher 
confidence interval (~95%), as calculated by confidence interval calculator by Mccallum-Layton, 
thereby making subsequent comparison amongst rest of data sets significant.  





NaN3 / DOG (37°C) ATP depletion 10 mM / 50 mM 1h 
NaN3 / DOG (4°C) ATP depletion + 
slows down 
metabolism 
10 mM / 50 mM 1h 
CPM Inhibits clathrin 
mediated endocytosis 
28 nM 1h 
Nystatin Inhibits lipid-raft 
mediated endocytosis 








Figure 22. MTT Assay evaluation of inhibitor efficiency of (A) NaN3/DOG at 37 °C, (B) chlorpromazine, (C) 
dynasore and (D) nystatin for different CNP formulations (5% v/v)  for fold-increase calculations.  A non-
synchronized population of HCC-1806 cells (10,000) was plated in 96 well plates for 24h before performing the 
treatments. Cells were first incubated with inhibitors for 1h followed by CNP formulation addition. Experiments 





Figure 23. Fold-increase values for different CNP formulations (5% v/v) in presence of (A) NaN3/DOG at 37 °C, 
(B) chlorpromazine, (C) dynasore and (D) was obtained via the cell-viability measurements.  From the Mccallum-
Layton calculator, a cut-off fold increase value of 1.30 was set, as it would lie on a higher confidence interval 
(~95%), thereby making subsequent comparisons amongst rest of data sets significant. Fold Increase greater than or 
equal to 1.30 was considered significant. 
 
It was interesting to observe that CNP Pristine internalized into the cells using a 
combination of energy dependent, clathrin dependent and lipid-raft pathway whereas CNP 
passivated with lecithin internalized the cells through all the four inspected endocytic pathways. 
However, since the variability in the calculation of fold-increase values for pristine CNP is lesser 
as compared to CNP Lecithin, it would have a higher probability of crossing the endocytic 
barrier. Remaining CNPs did not show any uptake for the investigated pathways. Parametric 
evaluation of surface charge and change from non-Triple negative breast cancer (TNBC), MCF-7 
to TNBC, HCC 1806 effects on internalization of CNPs can also be appreciated in a 3D map. 
(Figure 24) Results indicated that with the progression of non-TNBC to TNBC, less number of 
neutral and cationic CNPs show tendency for internalization via endocytic routes. For a TNBC 
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or non-TNBC cell-line, an initial screening of CNPs having different surface functionalities were 
done using the inhibitor assay. A combination of cell type (non-TNBC and TNBC) and CNP 
surface functionality type were assessed using the inhibitor assay to reach at a conclusion that as 
the cancer progresses from non-TNBC to TNBC, less number of neutral (CNP PEG 400, CNP 
PEG10K, CNP PEG20K and CNP Lec.) and cationic CNP (CNP PEI) show tendency for 
internalization via endocytic routes. 
 
Figure 24. Parametric evaluation of surface charge and change from non-triple negative breast cancer (TNBC), 
MCF-7 to TNBC, HCC 1806 effects on internalization of CNPs. As the cancer progresses non-TNBC to TNBC, less 




EFFECT OF TRIPLE DRUG COMBINATION SELECTIVELY ON TRIPLE 
NEGATIVE CELL POPULATION  
To verify the selective effect of drug cocktail on TNBC cells i.e. HCC 1806, MTT assay 
performed on TNBC HCC-1806 and results were compared with non-TNBC ER (+) MCF-7 
cells. Cytotoxicity was used as a measure for cellular entry due to its functional nature. It was 
considered as a better option as probability of getting false positive results could be minimized 
and can be neglected. Cells were treated with 25 µM concentration of NfF-kB modulator PTX, 
STAT3 modulator Nif and Topo-II modulator Am as individual drugs or in triple combination 
of PTX+Nif+Am for 48h before performing the MTT assay. IC50 values of CNP-drug, free 
drug, CNP-Tri and free Tri combination were calculated by plotting concentration versus cell 
viability, with concentrations ranging from 12.5 µM to 50 µM.  From this data, the concentration 
at which cell viability reached 50% was extrapolated, indicating the IC50 value.  A comparison 
of IC50 for HCC-1806 and MCF-7 cells showed no particular selectivity for PTX, Am 
and PTX+Nif+Am mixture treatments though Nif introduced a significant change in IC50 values 
as ~10 µM in MCF-7 compared to ~50 µM in HCC1806  (Figure 25A). A combinatorial index 
(CI) calculation on triple drug mixture (PTX+Nif+Am) compared to individual drugs was found 
to be at least two times more responsive for TNBC HCC-1806 cells (~0.6) compared to non-
TNBC MCF-7 cells (~1.2) (Figure 25B). A lower than one CI value (<1) represented the 
synergistic effect of drug mixture while higher than one (<1) representative of non-
communicating drug molecules and probably their action mechanism pathways in that particular 
cell lines. This was clear from the results that this drug mixture (PTX+Nif+Am) was synergistic 
in TNBC HCC1806 cells. Although three representative cell lines were used for the study, a 
significantly high number of CNPs with different surface functionality were scanned to reach a 
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conclusion. Therefore, a combination of cell type and parametrically screened CNP surface 
functionality makes it substantial to reach at a conclusion.  
 
Figure 25. MTT assay performed on TNBC HCC-1806 and non-TNBC ER (+) MCF-7 cells. Cells were incubated 
for 48h before performing the MTT assay. (A) Comparison of IC50 for HCC-1806 and MCF-7 cells when being 
treated with NfF-kB modulator PTX, STAT3 modulator Nif and Topo-II modulator Am as individual drugs or in 
triple combination of PTX+Nif+Am solubilized in DMSO. (B) Combinatorial index (CI) calculation on triple drug 
mixture compared to individual drugs as found to be at least two times more responsive for TNBC HCC-1806 cells 
compared to non-TNBC MCF-7 cells. 
 
EFFECT OF TRIPLE DRUG COMBINATION INCORPORATION IN CNPS ON CELL 
GROWTH DENSITY, MORPHOLOGY AND VIABILITY  
MTT assay performed in TNBC cells, HCC 1806 after incubation with various drug 
formulations for 48h were analyzed in terms of cell viability efficiency and their respective 
effects on cell growth density and morphology. Experiments were performed with 4 to 
70 µM concentration of PTX and Nif while Am from 1.25 to 20 µM as optimized for effective 
dose range in water, DMSO or loaded to CNPs in individual or combination form. Different 
70 
 
solution forms (water and DMSO solvents) were used to evaluate effect of solubility of drugs on 
cell viability (Figure 26).  
 
Figure 26. MTT assay performed in TNBC cells, HCC 1806 after incubation with various drug formulations for 
48h. PTX and Nif were used at a concentration range of 4 to 70 µM while Am from 1.25 to 20 µM as optimized for 
effective dose range. Concentration of drugs were same in water, DMSO or loaded to CNPs in individual or 
combination form. 
 
It was found the CNP-Tri comb was the best formulation with maximum cell death. 
Additionally, all CNP loaded drugs were better than free drugs in killing the cells at same 
concentration. DMSO dissolved drug molecules were found be more effective than water 
solubilized one probably due to improved solubility in DMSO. Am was found better 
than Nif and PTX in same order all across the formulation in different solvent or loaded to CNP.  
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Effects were further observed by studying cell morphology and growth density changes 
in TNBC cells, HCC 1806 after incubation with various drug formulations for 48h. PTX 
and Nif were used at a concentration range of 4 µM (low conc.) 70 µM (high conc) while Am 
from 1.25 (low conc.) and 20 µM (high conc) (Figure 27). A clear loss in cell density was 
reported for high concentrations of cells treated with CNP-Tri Comb with minimum effect in 
CNP-PTX treatments. Even at lower concentration CNP-Tri Comb was best formulation causing 




Figure 27. Cell morphology and growth density study performed in TNBC cells, HCC 1806 after incubation with 
various drug formulations for 48h. PTX and Nif were used at a concentration range of 4 µM (low conc.) 70 µM 
(high conc.) while Am from 1.25 (low conc.) and 20 µM (high conc.). 
  
PROTEIN EXPRESSION AS INDICATION OF EFFECTIVE DRUG COMBINATION  
Nifuroxazide inhibits STAT3 by blocking its dimerization and in turn phosphorylation 







High Conc. Low Conc.
Low cell density High cell density
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validate this, western blot analysis was performed to determine the effect of CNP-Tri Comb on 
the expression of phosphorylated STAT3. Western blot showing expression of the pSTAT3 
protein and β-actin extracted from cells treatment with 1: No treatment; 2: CNP-Am, 3: CNP-
Nif, 4: CNP-PTX and 5: CNP-Tri Comb (Figure 28A). It showed that CNP-Tri Comb treatment 
induced down regulation of phosphorylated STAT3 along with similar effects from CNP-
Nif treatments at the same concentration of Nif in CNP-Nif or form of triple drug mixture loaded 
in CNPs. On the other end, minimum to no difference in pSTAT3 protein expression 
was noticed between control and treated samples with CNP-PTX and CNP-Am. Gel 
quantification of expressed pSTAT3 protein respect to unaffected home protein β-actin was 
performed to reveal an approx. downregulation of 90% pSTAT3 for CNP-Nif and CNP-Tri 
Comb compare to just 30% for CNP-PTX and almost no effect by CNP-Am treatments 
(Figure 28B). Thus, it signifies the partial involvement of PTX, a NF-κB modulator, in STAT3 
signaling but none by TOPO-II modulator (Am) to start with but CI index calculation supported 




Figure 28. Effect of triple drug mixture treatment on HCC 1806 cells protein expression. (A) Western blot showing 
expression of pSTAT3 protein and β-actin extracted from cells treatment with 1: No treatment; 2: CNP-Am, 3: 
CNP-Nif, 4: CNP-PTX and 5: CNP-Tri Comb. (B) Quantification of expressed pSTAT3 protein respect to 
unaffected housekeeping protein β-actin. 
 
EFFECT OF CNP-TRI COMB ON TNBC XENOGRAFT TUMORS  
To evaluate the efficacy of triple drug combination loaded on CNPs in TNBCs, tumor 
regression experiments were performed in xenograft nude animal models. The drug cocktail 
showed maximum effect when encapsulated to CNPs in vitro. The effect was considerably better 
than drug combination alone and CNPs alone with no significant effect on cell death in all in-
vitro studies. As identified during in-vitro studies, CNP alone were not significant toxic and did 













































not contribute to overall effects of drug combination. The results from the in vitro studies were 
considered and in-vivo experiments were designed to minimize the use of vertebrate animals.  In 
order to detect at least 20% difference in tumor size, we decided to generate 4 tumors per animal 
as 3 mice per group and followed by tumor volume all along the experiment (Figure 
29A). Tumors grown to a minimum size of 5 × 5 mm (Figure 29B1 and C1) 
were intratumorally injected with phosphate buffer DPBS (Figure 29B1-B3) and CNP-Tri Comb 
(Figure 29C1-C3) in 60 µ L volume on day 0, 2, 4 and 6 days. The growth was followed by 
caliper and volume was calculated to compare the regression effect. The regression 
of tumor growth was found to be biologically significant for CNP-Tri Comb (Figure 29C3) 
compared to tumors treated with buffer (Figure 29B3) and could be summarized as tumor growth 
curves with time (Figure 29D). A percentage changes in tumor size after treatment with buffer 
(control) and CNP-Tri Comb was significantly visible at around 100% more growth in buffer 
control tumors compared CNP-Tri Comb treated tumors with in six days of first treatment 
(Figure 29E).  Here * represent the p < 0.05 and a bio-statistically significant difference in tumor 
size treated with CNP-Tri Comb compared to buffer control as obtained after performed t-
test. We recognize the biological barriers and complexity of systemic circulation presented by 
intravenous administration route. Thus, intratumoral administration route was chosen for 
simplification and to reach logical conclusions. An alternative administration route is therefore 
out of the scope of this immediate study but will be chosen as part of a future extension of this 





Figure 29. In vivo results on xenograft mouse model. (A) Timeline of experiment; (B, C) representative animals 
with tumors before and after treatment with (B) DPBS; (C) CNP-Tri Comb.  B1 and C1 represent animals with 
tumors before injections and B2 and C2 after injections while smaller size of tumors were seen in C3 compared to 
B3 at 6th day of measurement. (D) Tumor growth curves with time and (E) fold changes after treatment with buffer 
(control) and CNP-Tri Comb. * represent the p < 0.05 and a bio-statistically significant difference in tumor size 


















In this work, we demonstrated a combinatorial drug formulation comprising DNA 
damage repair agents, along with inhibitors for STAT-3 for an optimized effect. The 
combinatorial formulation included nifuroxazide, a known STAT-3 inhibitor, and amonafide, an 
agent known to exert its effect through topoisomerase-II activation pathways. An additional 
incorporation of pentoxifylline, a methylxanthine derivative known for anti-metastatic effects in 
breast cancers, could further improve the efficiency. We used drug combination 
of nifuroxazide, amonafide and pentoxifylline in HCC1806 (TNBC), along with non-TNBC 
breast cancer cells, MCF-7, to find the combinatorial index of the drug cocktail. It was found that 
combination of pentoxifylline (PTX), nifuroxazide (NIFU) and amonafide (AMF) resulted in a 
combinatorial index of 0.54 in HCC1806 cells. We also investigated the protein expression 
effects exerted by combination of drugs responsible to induce synergistic effect and 
simultaneously suppressing drug resistance through distinct mechanisms of action. Thus, our 
efforts might generate a novel triple drug combination as an answer to current TNBC related 
problems. We demonstrate that phenotypically stratified multi-compartmental nanoparticle is 
highly effective in delivering a novel combinatorial triple drug formulation for synergistic 
regression of TNBC in vitro and in vivo. Multicompartmental carbon nanoparticles were then 
parametrically assessed based on size, charge (positive/negative/neutral) and chemistry 
(functionalities) to study their likelihood of crossing endocytic barriers from phenotypical 
standpoint in various TNBC lines. Interestingly, a combination of clathrin mediated, energy and 
dynamin dependent pathways were predominant for sulfonated nanoparticles, whereas 
phospholipid particles followed all the investigated endocytic pathways. An exactitude ‘omics’ 
approach helps to predict that phospholipid encapsulated-particles will predominantly 
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accumulate in TNBC comprising the drug-‘cocktail’. After an exhaustive screening process for 
different CNPs based on their surface functionalities, the best “candidate” was chosen for in-vivo 
studies. However, by testing only one particle formulation, we could only draw conclusions on 
the therapeutic effect of this particular formulation. We investigated the gene and protein 
expression effects inducing synergistic effect and simultaneously suppressing drug resistance 
through distinct mechanisms of action. Overall, this work is aimed at identifying specific surface 
chemistries on carbon nanoparticles to facilitate its entry in TNBC and extrapolate such 
information in a real-world situation of cancer tumors with mixed population of TNBC and non-
TNBC. To the best of our knowledge, this is one of the earliest attempt to stratifying 
nanotherapeutics based on cancer phenotypes. We recognize the complexity of the disease and 
realize that optimization can only be achieved by conducting multiple studies beyond this 
preliminary communication. Successful outcome of these studies may have significant 













CHAPTER 4: OUTCOME OF STUDIES 
 In these studies, we developed a novel combinatorial therapy for TNBC. We determined 
that NIFU had a more therapeutic effect than NSL, and proceeded with NIFU as our STAT3 
inhibitory agent. Additionally, we assessed that 48 hours was a sufficient treatment time to 
observe a therapeutic effect in our 2D culture models. We tested our optimized combinatorial 
treatment in 4 TNBC cell lines and 2 control cell lines. Significant therapeutic effect was seen in 
all cell lines, but we observed a synergistic effect in some of the TNBC cell lines. We went 
further to test this combinatorial approach in a 3D culture model and saw promising results. 
 Following this optimization of drug combination, we utilized phenotypically stratified 
carbon nanoparticles to enhance drug delivery to the cells. Particles were assessed based on their 
size, charge and surface functionalities, and the ‘best’ CNP formulation was utilized. We 
encapsulated each single molecule and the triple combination with CNPs to assess cytotoxicity 
and saw maximum effect in CNP-Tri Comb. This particle was then used for in vivo studies and 
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APPENDIX A: ABBREVIATIONS 
TNBC – Triple negative breast cancer 
PTX – Pentoxifylline 
NSL - Niclosamide 
NIFU – Nifuroxazide 
AMF – Amonafide 
CNP – Carbon Nanoparticle 
CNP-Am – Amonafide Carbon Nanoparticle 
CNP-Nif – Nifuroxazide Carbon Nanoparticle 
CNP-PTX – Pentoxifylline Carbon Nanoparticle 
CNP-Tri Comb – Pentoxifylline + Nifuroxazide + Amonafide Carbon Nanoparticle 
 
 
